A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

March 16, 2022

Study Completion Date

July 14, 2022

Conditions

Contrast Enhancement in Magnetic Resonance Imaging

Interventions

DRUG

BAY1747846

Solution for intravenous (IV) injection, single dose

Trial Locations (2)

Clinical Pharmacology of Miami, LLC, Miami

Alliance for Multispecialty Research, LLC - Knoxville, Knoxville